利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.031 秒)

    Mice lacking inward-rectifying potassium channel Kir6.1
    4.
    发明授权
    Mice lacking inward-rectifying potassium channel Kir6.1 失效
    小鼠缺乏内向整流钾通道Kir6.1

    公开(公告)号：US07115797B2

    公开(公告)日：2006-10-03

    申请号：US10388005

    申请日：2003-03-14

    申请人： Susumu Seino ,  Takashi Miki ,  Haruaki Nakaya

    发明人： Susumu Seino ,  Takashi Miki ,  Haruaki Nakaya

    IPC分类号： A01K67/027

    CPC分类号： C12N15/8509 ,  A01K67/0276 ,  A01K2217/075 ,  A01K2227/105 ,  A01K2267/03 ,  A01K2267/0375 ,  C07K14/705

    摘要： Mice homozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are disclosed. The mice causes a high incidence of sudden death associated with arrhythmia (atrioventricular block) caused by spontaneous cardiac ischemia, a condition similar to Prinzmetal angina (variant angina) in human, representing an animal model of Prinzmetal angina. Mice heterozygous for the lack of inward-rectifying potassium channel Kir6.1 gene are also disclosed, which are used as parent mice for reproduction of the homozygous mice.

    摘要翻译： 公开了缺乏内向整流钾通道Kir6.1基因的纯合子的小鼠。 这种小鼠导致与自发性心肌缺血引起的心律失常（房室传导阻滞）相关的猝死率高，这与人类中的Prinzmetal心绞痛（变异型心绞痛）相似，是Prinzmetal心绞痛的动物模型。 还公开了缺乏内向整流钾通道Kir6.1基因的杂合子，其用作繁殖纯合小鼠的母体小鼠。

    METHOD OF SCREENING FOR INSULIN SECRETION-POTENTIATING AGENTS
    5.
    发明申请
    METHOD OF SCREENING FOR INSULIN SECRETION-POTENTIATING AGENTS 审中-公开
    胰岛素分泌潜能试剂筛选方法

    公开(公告)号：US20120082976A1

    公开(公告)日：2012-04-05

    申请号：US13264391

    申请日：2010-04-15

    申请人： Susumu Seino ,  Changliang Zhang ,  Megumi Kato ,  Tadao Shibazaki

    发明人： Susumu Seino ,  Changliang Zhang ,  Megumi Kato ,  Tadao Shibazaki

    IPC分类号： C12Q1/68 ,  C07K19/00 ,  C12N15/85 ,  C12N5/10 ,  C12N15/62 ,  C12N15/63

    CPC分类号： C07K14/4702 ,  G01N33/5308 ,  G01N33/542 ,  G01N2333/62 ,  G01N2500/10

    摘要： Disclosed are a novel method of screening for insulin secretion-potentiating agents as well as means for performing such screening. The means include a DNA encoding fluorescent-labeled Epac2 comprising two different DNAs encoding two different fluorescent proteins which emit fluorescent light with wavelength differing from each other and a DNA encoding Epac2 which are fused together in-frame, and the cells transformed with the DNA. Also disclosed is a method of screening insulin secretion-potentiating agents comprising bringing a candidate compound into contact with cells transformed with the said DNA, and detecting whether the compound binds to Epac2.

    摘要翻译： 公开了一种筛选胰岛素分泌增强剂的新方法以及进行这种筛选的方法。 该方法包括编码荧光标记的Epac2的DNA，其包含两种不同的DNA，其编码两种不同的荧光蛋白，其发射彼此波长不同的荧光，以及编码融合在一起的Epac2的DNA，以及用DNA转化的细胞。 还公开了筛选胰岛素分泌增强剂的方法，包括使候选化合物与用所述DNA转化的细胞接触，并检测该化合物是否结合Epac2。

    BLOOD INSULIN RESISTANCE AND DIABETES MARKER PROGRANULIN, METHOD FOR ANALYZING CONCENTRATION OF PROGRANULIN IN BLOOD SAMPLE, AND METHOD FOR SCREENING FOR SUBSTANCE THAT IMPROVES INSULIN RESISTANCE AND IMPROVES OR SUPPRESSES DIABETES
    6.
    发明申请
    BLOOD INSULIN RESISTANCE AND DIABETES MARKER PROGRANULIN, METHOD FOR ANALYZING CONCENTRATION OF PROGRANULIN IN BLOOD SAMPLE, AND METHOD FOR SCREENING FOR SUBSTANCE THAT IMPROVES INSULIN RESISTANCE AND IMPROVES OR SUPPRESSES DIABETES 审中-公开
    血清抗胰蛋白酶抗性和糖尿病标记物，用于分析血清样品浓度的方法，以及用于筛选改善胰岛素抵抗和改善或抑制糖尿病的物质的方法

    公开(公告)号：US20130210039A1

    公开(公告)日：2013-08-15

    申请号：US13819704

    申请日：2011-07-13

    申请人： Toshiya Matsubara ,  Makoto Watanabe ,  Susumu Seino ,  Kohtaro Minami ,  Osamu Nishimura ,  Ayako Mita

    发明人： Toshiya Matsubara ,  Makoto Watanabe ,  Susumu Seino ,  Kohtaro Minami ,  Osamu Nishimura ,  Ayako Mita

    IPC分类号： G01N33/68

    CPC分类号： G01N33/6893 ,  G01N2333/475 ,  G01N2500/00 ,  G01N2500/10 ,  G01N2800/042

    摘要： The present invention provides a marker capable of detecting insulin resistance and diabetes in a collected blood sample, a method for analyzing said marker, a method for screening a substance improving insulin resistance, and improving or suppressing diabetes. A blood insulin resistance marker and a blood diabetes marker, which comprises a polypeptide comprising at least 15 continuous amino acids in an amino acid sequence constituting progranulin. A method for analyzing a blood marker, which comprises the steps of: measuring a concentration of an insulin resistance marker or a diabetes marker in a collected blood sample; and comparing the measured concentration with a normal blood concentration of the marker. A method for screening a substance improving insulin resistance, and improving or suppressing diabetes, which comprises the steps of: administering a candidate substance to a living body expressing insulin resistance or suffering from diabetes; measuring a blood concentration of a marker in the living body after administration; and comparing the measured concentration of the marker with a blood concentration of the marker not administered with the candidate substance.

    摘要翻译： 本发明提供能够检测收集的血液样品中的胰岛素抵抗和糖尿病的标记物，分析所述标记物的方法，用于筛选改善胰岛素抵抗的物质的方法，以及改善或抑制糖尿病。 一种血液胰岛素抵抗标记物和血液糖尿病标志物，其包含在构成颗粒体蛋白前体的氨基酸序列中包含至少15个连续氨基酸的多肽。 一种分析血液标记物的方法，包括以下步骤：测量所收集的血液样品中胰岛素抵抗标志物或糖尿病标志物的浓度; 并将测量的浓度与标记物的正常血液浓度进行比较。 一种筛选改善胰岛素抵抗的物质，改善或抑制糖尿病的方法，包括以下步骤：将候选物质施用于表达胰岛素抵抗或患有糖尿病的活体; 测定给药后的生物体中的标记物的血液浓度; 并将标记物的测定浓度与未施用候选物质的标记物的血液浓度进行比较。

    Operation condition setting system
    7.
    发明申请
    Operation condition setting system 失效
    操作条件设定系统

    公开(公告)号：US20070091752A1

    公开(公告)日：2007-04-26

    申请号：US10554241

    申请日：2005-02-22

    申请人： Atsushi Watanabe ,  Junichi Horigome ,  Masayoshi Nagaya ,  Masatoshi Nishino ,  Susumu Seino ,  Masahiro Uchida

    发明人： Atsushi Watanabe ,  Junichi Horigome ,  Masayoshi Nagaya ,  Masatoshi Nishino ,  Susumu Seino ,  Masahiro Uchida

    IPC分类号： G11B7/00

    CPC分类号： G11B7/00456 ,  G11B7/0045 ,  G11B7/00736 ,  G11B2007/0006

    摘要： The present invention makes it possible to set an operating condition enabling the best recording characteristic to be obtained for any kind of recording media, even in the case where the recording medium is combined with any kind of drive devices. According to the present invention, even in the case where a unknown and new kind of recording medium is loaded into the drive device, a piece of first operating condition information for an optical system suitable for a combination of the drive device and the new kind of recording media is read from a specific read only area provided for the recording medium, and an operating condition enabling the best operating characteristic to be obtained is set by using the first operating condition information, as a result of which even in the case where any kind of recording medium and any kind of drive device are combined, the operating condition for enabling the best recording characteristic to be obtained for the recording medium, can be set in the drive device.

    摘要翻译： 本发明即使在记录介质与任何种类的驱动装置组合的情况下，也可以为任何类型的记录介质设置能够获得最佳记录特性的操作条件。 根据本发明，即使在未知和新型的记录介质被装载到驱动装置中的情况下，也可以使用适于驱动装置和新型记录媒体的组合的光学系统的第一操作条件信息 从为记录介质提供的特定的只读区域读取记录介质，并且通过使用第一操作条件信息来设置能够获得最佳操作特性的操作条件，结果即使在任何类型的情况下 的记录介质和任何种类的驱动装置组合，可以在驱动装置中设置用于使记录介质获得最佳记录特性的操作条件。

    Protein Rim2
    8.
    发明授权
    Protein Rim2 失效
    蛋白质Rim2

    公开(公告)号：US06956104B2

    公开(公告)日：2005-10-18

    申请号：US10180326

    申请日：2002-06-27

    申请人： Susumu Seino ,  Tadao Shibasaki ,  Nobuaki Ozaki

    发明人： Susumu Seino ,  Tadao Shibasaki ,  Nobuaki Ozaki

    IPC分类号： C12N15/09 ,  C07K14/435 ,  C07K14/47 ,  C07K16/18 ,  C12P21/08 ,  C12Q1/68 ,  G01N33/53 ,  C07K14/00 ,  A61K38/00 ,  C12N15/00 ,  C12P21/04

    CPC分类号： C07K14/4722

    摘要： Provided is a protein used in the development of a therapeutic agent for neuron- or endocrine cell-related diseases, in which the transport system is involved. The protein has an amino acid sequence with one or more amino acids deleted, substituted, inserted or added relative to the amino acid sequence set forth under SEQ ID NO:1 in the Sequence Listing and which has a property to interact with GDP/GTP exchange factor II.

    摘要翻译： 提供了用于开发涉及运输系统的神经元或内分泌细胞相关疾病的治疗剂的蛋白质。 蛋白质具有相对于序列表中SEQ ID NO：1所示的氨基酸序列缺失，取代，插入或添加的一个或多个氨基酸的氨基酸序列，其具有与GDP / GTP交换相互作用的性质 因素二。

    Induction of Insulin Secreting Cell
    9.
    发明申请
    Induction of Insulin Secreting Cell 审中-公开
    诱导胰岛素分泌细胞

    公开(公告)号：US20070231897A1

    公开(公告)日：2007-10-04

    申请号：US11628202

    申请日：2005-05-26

    申请人： Susumu Seino ,  Kohtaro Minami ,  Masaaki Okuno ,  Kazumasa Miyawaki

    发明人： Susumu Seino ,  Kohtaro Minami ,  Masaaki Okuno ,  Kazumasa Miyawaki

    IPC分类号： C12N5/08 ,  C12N5/02

    CPC分类号： C12N5/0676 ,  C12N2501/11 ,  C12N2501/117 ,  C12N2501/119 ,  C12N2501/12

    摘要： Disclosed is a method for producing insulin secreting cells to be used in cell transplantation therapy of diabetes, by induction from pancreatic acinar cells in culture vessels. The method comprises culturing pancreatic acinar cells isolated from a mammal in a medium containing a growth factor, preferably epidermal growth factor, fibroblast growth factor and/or hepatocyte growth factor, to induce insulin secreting cells.

    摘要翻译： 公开了通过从培养容器中的胰腺腺泡细胞诱导，用于产生用于糖尿病的细胞移植治疗的胰岛素分泌细胞的方法。 该方法包括在含有生长因子，优选表皮生长因子，成纤维细胞生长因子和/或肝细胞生长因子的培养基中培养从哺乳动物分离的胰腺腺泡细胞，以诱导胰岛素分泌细胞。

    Sodium ion-driven chloride /bi-carbonate exchanger
    10.
    发明授权
    Sodium ion-driven chloride /bi-carbonate exchanger 失效
    钠离子驱动的氯化物/双碳酸盐交换器

    公开(公告)号：US06673899B2

    公开(公告)日：2004-01-06

    申请号：US09920804

    申请日：2001-08-03

    申请人： Susumu Seino ,  Hideki Yano ,  Changzheng Wang

    发明人： Susumu Seino ,  Hideki Yano ,  Changzheng Wang

    IPC分类号： C07K14705

    CPC分类号： C07K14/705

    摘要： The present invention discloses DNAs comprising nucleotide sequences set forth as SEQ ID NO:1 or NO:3 encoding Na+-driven Cl—/HCO3— exchanger, proteins comprising amino acid sequences set forth as SEQ ID NO:2 or NO:4, and their homologous proteins comprising an amino acid sequence having deletion, substitution, addition or insertion amino acids, which proteins, when expressed in a cell, functions as Na+-driven Cl—/HCO3— exchanger, and cells in which the proteins exogenously expressed.

    摘要翻译： 本发明公开了包含编码Na +驱动的Cl- / HCO 3 - 交换体的SEQ ID NO：1或NO：3所示的核苷酸序列的DNA，包含SEQ ID NO：2或NO： 4及其包含具有缺失，取代，添加或插入氨基酸的氨基酸序列的同源蛋白质，当在细胞中表达时，这些蛋白质用作Na +驱动的Cl- / HCO 3 - 交换剂，以及其中 外源表达的蛋白质。